Back to Search

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma

  • Protocol Number: 202006003
  • Principal Investigator: Picus, Joel
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions